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Randomised controlled trials (RCTs)
must be internally valid (i.e., design
and conduct must eliminate the
possibility of bias), but to be clinically
useful,theresultmustalsoberelevantto
a deﬁnable group of patients in a
particular clinical setting (i.e., they
must be externally valid). Lack of
external validity is the most frequent
criticism by clinicians of RCTs,
systematic reviews, and guidelines, and
is one explanation for the widespread
underuse in routine practice of
many treatments that have been shown
to be beneﬁcial in trials and are
recommended in guidelines [1]. Yet
medical journals, funding agencies,
ethics committees, the pharmaceutical
industry, and governmental regulators
seem to give external validity a low
priority. Admittedly, whereas the
determinants of internal validity are
intuitive and can generally be worked
out from ﬁrst principles, understanding
of the determinants of the external
validity of an RCT requires clinical
rather than statistical expertise, and
often depends on a detailed
understanding of the particular clinical
condition under study and its
management in routine clinical
practice. However, reliable judgments
about the external validity of RCTs are
essential if treatments are to be used
correctly in as many patients as possible
in routine clinical practice.
The results of RCTs or systematic
reviews will never be relevant to all
patients and all settings, but they should
be designed and reported in a way that
allows clinicians to judge to whom the
results can reasonably be applied. Table 1
lists some of the important potential
determinants of external validity, each
of which is reviewed brieﬂy below. Many
of the considerations will only be relevant
in certain types of trials, for certain
interventions, or in certain clinical
settings, but they can each sometimes
undermine external validity. Moreover,
the list is not exhaustive and requires
more detailed annotation and
explanation than is possible in this short
review.
Some of the issues that determine
external validity are relevant to the
distinction between pragmatic trials and
explanatory trials [2], but it would be
wrong to assume that pragmatic trials
necessarily have greater external validity
than explanatory trials. For example,
broad eligibility criteria, limited
collection of baseline data, and inclusion
of centres with a range of expertise and
differing patient populations have many
advantages, but they can also make it very
difﬁcult to generalise the overall average
effect of treatment to a particular clinical
setting.
The Setting of the Trial
A detailed understanding of the setting
in which a trial is performed, including
any peculiarities of the health-care
system in particular countries, can be
essential in judging external validity. The
potential impact of differences between
health-care systems is illustrated by the
analysis of the results of the European
Carotid Surgery Trial (ECST) [3], an
RCT of endarterectomy for recently
symptomatic carotid stenosis, in Figure
1. National differences in the speed with
which patients were investigated, with a
median delay from last symptoms to
randomisation of greater than two
months in the United Kingdom (slow
centres) compared with three weeks in
Belgium and Holland (fast centres),
resulted in very different treatment
effects in these different health-care
systems—due to the shortness of the time
window for effective prevention of stroke.
Similar differences in performance
between health-care systems will exist for
other conditions, and there is, of course,
the broader issue of how trials done in the
developed world apply in the developing
world. Moreover, other differences
between countries in the methods of
diagnosis and management of disease—
which can be substantial—or important
racialdifferencesinpathologyandnatural
history of disease also affect the external
validity of RCTs. A good example is the
heterogeneity of results of trials of bacilli
calmette guerin vaccination in prevention
of tuberculosis, with a progressive loss of
efﬁcacy (p , 0.0001) and with decreasing
latitude [4].
How centres and clinicians were
selected to participate in trials is seldom
reported, but can also have important
implications for external validity. For
example, the Asymptomatic Carotid
Artery Study (ACAS) trial of
endarterectomy for asymptomatic
carotid stenosis only accepted surgeons
with an excellent safety record, rejecting
40% of applicants initially, and
subsequently barring from further
participation those who had adverse
operative outcomes in the trial. The
beneﬁt from surgery in ACAS was due in
major part to the consequently low
operative risk [5]. A meta-analysis of 46
surgical case series that published
operative risks during the ﬁve years after
ACAS found operative mortality to be
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and death to be about three times higher
[1]. Trials should not include centres that
do not have the competence to treat
patients safely, but selection should not
be so exclusive that the results cannot be
generalised to routine clinical practice.
Selection and Exclusion of
Patients
Concern is often expressed about highly
selective trial eligibility criteria, but there
are often several earlier stages of
selection that are rarely recorded or
reported but which can be more
problematic. For example, consider a
trial of a new blood pressure–lowering
drug, which like most such trials is
performed in a hospital clinic. Fewer
than 10% of patients with hypertension
are managed in hospital clinics, and this
group will differ from those managed in
primary care. Moreover, only one of the
ten physicians who see hypertensive
patients in this particular hospital is
taking part in the trial, and this
physician mainly sees young patients
with resistant hypertension. Thus, even
before any consideration of eligibility or
exclusion criteria, potential recruits are
already very unrepresentative of patients
in the local community. It is essential
therefore that, where possible, trials
record and report the pathways to
recruitment.
Patients are then further selected
according to trial eligibility criteria.
Some RCTs exclude women and many
exclude the elderly and/or patients with
common comorbidities. One review of
214 drug trials in acute myocardial
infarction (MI) found that over 60%
excluded patients aged over 75 years [6],
despite the fact that over 50% of MIs
occur in this older age group. A review of
41 United States National Institutes of
Health RCTs found an average exclusion
rate of 73% [7], but rates can be much
higher. One study of the eligibility
criteria of an acute stroke treatment
trial found that of the small proportion
of patients admitted to hospital in time to
be suitable for treatment, 96% were
ineligible based on the various other
exclusion criteria [8]. One centre in
another acute stroke trial had to screen
192 patients over two years to ﬁnd an
eligible patient [9]. Yet, highly selective
recruitment is not inevitable. The GISSI-1
trial of thrombolysis for acute MI, for
example, recruited 90% of patients
admitted within 12 hours of the event
with a deﬁnite diagnosis and no
contraindications [10].
Strict eligibility criteria can limit the
external validity of RCTs, but physicians
should at least be able to select similar
patients for treatment in routine
practice. Unfortunately, however,
reporting of trial eligibility criteria is
frequently inadequate. A review of trials
leading to clinical alerts by the US
National Institutes of Health revealed
that of an average of 31 eligibility
criteria, only 63% were published in the
main trial report and only 19% in the
clinical alert [11]. Inadequate reporting is
also a major problem in secondary
publications, such as systematic reviews
and clinical guidelines, where the need
for a succinct message does not usually
allow detailed consideration of the
eligibility and exclusion criteria or other
determinants of external validity.
Prerandomisation run-in periods are
also often used to select or exclude
patients. In a placebo run-in, all eligible
patients receive placebo, and those who
are poorly compliant are excluded. There
can be good reasons for doing this, but
high rates of exclusion will reduce
external validity. Active treatment run-in
periods in which patients who have
adverse events or show signs that
treatment may be ineffective are
excluded are more likely to undermine
.......................................................................................................................
Table 1. Main Issues That Can Affect External Validity and Should Be Addressed in
Reports of the Results of Randomised Controlled Trials or Systematic Reviews and
Considered by Clinicians
Issue Example
Setting of the trial Health-care system
Country
Recruitment from primary, secondary, or tertiary care
Selection of participating centres
Selection of participating clinicians
Selection of patients Methods of prerandomisation diagnosis and investigation
Eligibility criteria
Exclusion criteria
Placebo run-in period
Treatment run-in period
‘‘Enrichment’’ strategies
Ratio of randomised patients to eligible nonrandomised
patients in participating centres
Proportion of patients who declined randomisation
Characteristics of randomised patients Baseline clinical characteristics
Racial group
Uniformity of underlying pathology
Stage in the natural history of their disease
Severity of disease
Comorbidity
Absolute risks of a poor outcome in the control group
Differences between trial
protocol and routine practice Trial intervention
Timing of treatment
Appropriateness/relevance of control intervention
Adequacy of nontrial treatment—both intended and actual
Prohibition of certain nontrial treatments
Therapeutic or diagnostic advances since trial was performed
Outcome measures and follow-up Clinical relevance of surrogate outcomes
Clinical relevance, validity, and reproducibility of complex scales
Effect of intervention on most relevant components of
composite outcomes
Identification of who measured outcome
Use of patient-centred outcomes
Frequency of follow-up
Adequacy of the length of follow-up
Adverse effects of treatment Completeness of reporting of relevant adverse effects
Rates of discontinuation of treatment
Selection of trial centres and/or clinicians on the basis of skill or
experience
Exclusion of patients at risk of complications
Exclusion of patients who experienced adverse effects during a
run-in period
Intensity of trial safety procedures
DOI: 10.1371/journal.pctr.0010009.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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of carvedilol, a vasodilatory beta-blocker,
in chronic heart failure excluded 6% and
9%ofeligiblepatientsintreatmentrun-in
periods—mainly because of worsening
heart failure and other adverse events,
some of which were fatal [1]. In both trials,
the complication rates in the subsequent
randomised phase were much lower than
in the run-in phase.
Trials also sometimes actively recruit
patients who are likely to respond well to
treatment (often termed ‘‘enrichment’’).
For example, some trials of antipsychotic
drugs have selectively recruited patients
who have previously had a good response
to antipsychotics [1]. Other trials have
excluded nonresponders in a run-in
phase. One RCT of a cholinesterase
inhibitor, tacrine, in Alzheimer disease
recruited 632 patients to a six-week
‘‘enrichment’’ phase in which they were
randomised to different doses of tacrine
versus placebo [12]. After a washout
period, only the 215 (34%) patients who
had a measured improvement on tacrine
in the ‘‘enrichment’’ phase were
randomised to tacrine (at their best
dose) versus placebo in the main phase
of the trial. External validity is clearly
undermined here.
Characteristics of Randomised
Patients
Even in large pragmatic trials with very
few exclusion criteria, recruitment of less
than 10% of potentially eligible patients
in participating centres is common.
Those patients who are recruited
generally differ from those who are
eligible but not recruited in terms of
age, sex, race, severity of disease,
educational status, social class, and place
of residence. The outcome in patients
included in RCTs is also usually better
than those not in trials, often markedly
so, not because of better treatment but
because of a better baseline prognosis.
Trial reports usually include the baseline
clinical characteristics of randomised
patients, so it is argued that clinicians
can assess external validity by comparison
with their patients. However, recorded
baseline clinical characteristics often say
very little about the real makeup of the
trial population, and can sometimes be
misleading. For example, Table 2 shows
t h eb a s e l i n ec l i n i c a lc h a r a c t e r i s t i c so f
patients randomised to warfarin in two
RCTs of secondary prevention of stroke
[1]. In one trial, patients were in atrial
ﬁbrillation, and in the other they were in
sinus rhythm, but the characteristics of
DOI: 10.1371/journal.pctr.0010009.g001
Figure 1. The Absolute Reductions in the Five-Year Risks of Ipsilateral Ischaemic Stroke
(Top) and Any Stroke or Death (Bottom) with Surgery in European Carotid Surgery Trial
Centres in Which the Median Delay from Last Symptomatic Event to Randomisation Was
Less than or Equal to 50 Days (Fast Centres) Compared with Centres with a Longer
Delay (Slow Centres)
Data are shown separately for patients with moderate (50%–69%) and severe (70%–99%) carotid stenosis.
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similar. However, the risk of intracranial
haemorrhage on warfarin was 19 times
higher (p , 0.0001) in Stroke Prevention
in Reversible Ischaemia Trial (SPIRIT)
than in the European Atrial Fibrillation
Trial (EAFT), even after adjustment for
differences in baseline clinical
characteristics and the intensity of
anticoagulation [13]. In judging external
validity, an understanding of how
patients were referred, investigated, and
diagnosed (i.e., their pathway to
recruitment), as well as how they were
subsequently selected and excluded, is
often much more informative than a list
of baseline characteristics.
The Intervention, Control
Treatment, and Pre-trial or
Nontrial Management
External validity can also be affected if
trials have protocols that differ from usual
clinical practice. For example, prior to
randomisation in the RCTs of
endarterectomy for symptomatic carotid
stenosis, patients had to be diagnosed by a
neurologist and have conventional
arterial angiography, neither of which
are routine in many centres. The trial
intervention itself may also differ from
that used in current practice, such as in
the formulation and bioavailability of a
drug, or the type of anaesthetic used for
an operation. The same can be true of the
treatment in the control group in a trial,
which may use a particularly low dose of
the comparator drug, or fall short of best
current practice in some other way.
External validity can also be undermined
by too stringent limitations on the use of
nontrial treatments. Any prohibition of
nontrial treatments should be reported in
the main trial publications, along with
details of relevant nontrial treatments
that were used. The timing of many
interventions is also critical and should
be reported when relevant.
Outcome Measures and
Follow-Up
The external validity of an RCT also
depends on whether the outcomes were
clinically relevant. Many trials use
‘‘surrogate’’ outcomes, usually biological
or imaging markers that are thought to be
indirect measures of the effect of
treatment on clinical outcomes. However,
as well as being of questionable clinical
relevance, surrogate outcomes are often
misleading. There are many examples of
treatments that have had a major
beneﬁcial effect on a surrogate outcome,
which had previously been shown to be
correlatedwitharelevantclinicaloutcome
in observational studies, but where the
treatments have proved ineffective or
harmful in subsequent large RCTs that
used these same clinical outcomes [1].
Complex scales, often made up of
arbitrary combinations of symptoms and
clinical signs, are also problematic. A
review of 196 RCTs in rheumatoid
arthritis identiﬁed more than 70
different outcome scales [14]. More
worryingly, a review of 2,000 RCTs in
schizophrenia identiﬁed 640 scales—
many of which were devised for the
particular RCT and had no supporting
data on validity or reliability, but which
were more likely to show statistically
signiﬁcant treatment effects than
established scales [15]. Moreover, the
clinical meaning of apparent treatment
effects (e.g., a 2.7-point mean reduction in
a 100-point outcome scale made up of
various symptoms and signs) is usually
impossible to discern. Simple clinical
outcomes usually have most external
v a l i d i t y ,b u t ,e v e nt h e n ,o n l yi ft h e y
reﬂect the priorities of patients. For
example, patients with epilepsy are much
more interested in the proportion of
individuals rendered free of seizures in
RCTs of anticonvulsants than they are in
changes in mean seizure frequency.
Identifying who actually measured the
outcome can also be important. For
example, the recorded operative risk of
stroke due to carotid endarterectomy is
highly dependent on whether patients
were assessed by a surgeon or a
neurologist [16].
Many trials combine events in their
primary outcome measure. This can
produce a useful measure of the overall
effect of treatment on all the relevant
outcomes, and it usually affords greater
statistical power, but the outcome that is
most important to a particular patient
may be affected differently by treatment
than the combined outcome. Composite
outcomes also sometimes combine events
of very different severity, and treatment
effects can be driven by the least
important outcome, which is often the
most frequent. Equally problematic is the
composite of deﬁnite clinical events and
episodes of hospitalisation. The fact that
a patient is in an RCT will probably affect
the likelihood of hospitalisation, and it
w i l lc e r t a i n l yv a r yb e t w e e nd i f f e r e n t
health-care systems.
Another major problem for the
external validity of RCTs is an
inadequate duration of treatment and/or
follow-up. For example, although patients
with refractory epilepsy or migraine
require treatment for many years, most
RCTs of new drugs look at the effect of
treatment for only a few weeks. Whether
initial response is a good predictor of
long-term beneﬁt is unknown. The same
problem has been identiﬁed in RCTs in
schizophrenia, with fewer than 50% of
trials having greater than six-week follow-
up, and only 20% following patients for
longer than six months [17]. The contrast
between beneﬁcial effects of treatments
.......................................................................................................................
Table 2. The Baseline Clinical Characteristics and Haemorrhage Outcomes of Patients
Randomised to Anticoagulation with Warfarin in EAFT and SPIRIT
Measurement Criterion SPIRIT (n ¼ 651) EAFT (n¼225)
Baseline clinical characteristics Male sex 66% 55%
Age . 65 years 47% 81%
Hypertension 39% 48%
Angina 9% 11%
Myocardial infarction 9% 7%
Diabetes 11% 12%
Leukoariosis on computerised
tomography brain scan
7% 14%
Outcomes during trial Mean (standard deviation)
international normalized ratio
during trial
3.3 (1.1) 2.9 (0.7)
Patient-years of follow-up 735 507
Intracranial haemorrhage 27 0
a
Extracranial haemorrhage 26 13
Adjusted hazard ratio
(95% confidence interval)
a
Intracranial haemorrhage 19.0 (2.4–250) p , 0.0001
Extracranial haemorrhage 1.9 (0.8–4.7) p ¼ 0.15
aThere were no proven intracranial haemorrhages, but no computerised tomography scan was performed in two
strokes. For the purpose of calculation of the adjusted hazard ratio for haemorrhage, these two strokes were
categorised as having been due to intracranial haemorrhage.
DOI: 10.1371/journal.pctr.0010009.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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encouraging experience of long-term
treatment in clinical practice has also
been highlighted by clinicians treating
patients with rheumatoid arthritis [18].
Adverse Effects of Treatment
Reporting of adverse effects of treatment
in RCTs and systematic reviews is often
poor. In a review of 192 pharmaceutical
trials, less then a third had adequate
reporting of adverse clinical events or
laboratory toxicology [19]. Treatment
discontinuation rates provide some
guide to tolerability, but pharmaceutical
trials often use eligibility criteria and run-
in periods to exclude patients who might
be prone to adverse effects.
Clinicians are usually most concerned
about external validity of RCTs of
potentially dangerous treatments.
Complications of medial interventions
are a leading cause of death in
developed countries. Risks can be
overestimated in RCTs, particularly
during the introduction of new
treatments when trials are often done in
patients with very severe disease, but
stringent selection of patients,
conﬁnement to specialist centres, and
intensive safety monitoring usually lead
to lower risks than routine clinical
practice. RCTs of warfarin in
nonrheumatic atrial ﬁbrillation are good
examples. All trials reported beneﬁt
with warfarin, but complication rates
were much lower than in routine
practice, and consequent doubts about
external validity are partly to blame for
major underprescribing of warfarin,
particularly in the elderly [1].
CONCLUSIONS
Some trials have excellent external
validity, but many do not, particularly
some of those performed by the
pharmaceutical industry. Yet
researchers, funding agencies, ethics
committees, medical journals, and
governmental regulators all neglect
proper consideration of external
validity. Judgment is left to clinicians,
but reporting of the determinants of
external validity in trial publications,
and particularly in secondary reports
and clinical guidelines, is rarely
adequate and much relevant
information is never published. RCTs
cannot be expected to produce results
that are directly relevant to all patients
and all settings, but to be externally valid
they should at least be designed and
reported in a way that allows clinicians
to judge to whom they can reasonably be
applied. A consensus is required on how
the design and reporting of trials could
be improved in order to achieve this aim.
Agreement on a list of the most
important issues that should be
considered by clinicians and researchers
would be a helpful ﬁrst step. “
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